Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.

Autor: Zhao, Guangjian, Lin, Fanzhen, Wang, Ziran, Shao, Xiaolin, Gong, Yanxue, Zhang, Shirui, Cui, Yansen, Yang, Daiqun, Lei, Hongyan, Cheng, Zhongrong, Wang, Liquan, Guo, Dongdong, Zhang, Qinghua
Předmět:
Zdroj: European Neurology; 2019, Vol. 82 Issue 4/6, p93-98, 6p, 2 Charts, 1 Graph
Abstrakt: Objective: To verify the efficacy and safety of dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke (AMIS). Methods: AMIS patients who received recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis from January to October 2018 were retrospectively analyzed and divided into the aspirin (ASP) and ASP + clopidogrel (ASP-CLO) groups based on the type of antiplatelet therapy to compare the rates of good clinical outcome, symptomatic intracranial hemorrhage (SICH) after thrombolysis, and mortality in 90 days. Results: A total of 207 patients were included (group ASP, 105 patients; group ASP-CLO, 102 patients). There was no significant difference in the baseline clinical data between the 2 groups. The -90-day modified Rankin scale scores (66.7 vs. 82.4%, p = 0.009) showed a statistically significant difference, but SICH (1.0 vs. 1.0%, p = 0.917) and 90-day mortality (1.9 vs. 1.0%, p = 0.585) showed no significant difference between the 2 groups. Conclusions: Short-term (21 days) dual antiplatelet therapy after rt-PA intravenous thrombolysis for AMIS can improve the prognosis, reduce the risk of stroke recurrence, without increasing the risk of bleeding and mortality. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index